• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, April 27

Ranbaxy Laboratories has received approval from the US Food and Drug Administration to manufacture and market generic versions of the insomnia drug, Ambien. The approval is for 5mg and 10mg tablets of Zolpidem Tartrate, the company said in an e-mailed statement. According to the company, the Office of Generic Drugs, US FDA, has determined Ranbaxy's formulation to be bioequivalent to Sanofi Aventis' registered drug Ambien. The product is to be manufactured at the company's New Jersey facility, Ohm Laboratories. The annual market sales of the drug in the US are estimated at $2.12 billion, according to Ranbaxy.

More Stories on : Announcements | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
2 Lupin projects selected for funding

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line